Dasatinib and Quercetin represent the first senolytic combination studied in humans, marking a significant advancement in aging research. Senolytics are agents that selectively eliminate senescent cells, which accumulate with age and contribute to various age-related diseases. Dasatinib, a cancer drug, and Quercetin, a natural flavonoid found in many fruits and vegetables, work synergistically to target and remove these harmful cells. Early human studies have demonstrated the potential of this combination to improve physical function and reduce markers of cellular senescence, offering promising avenues for therapies aimed at enhancing healthspan and treating age-associated conditions.